Find a specific notice:

A revocation to this notice was published on 21 March 2022, Notice No. 2022-go1009.

Notice Type
Departmental
Notice Title

Specification of COVID-19 Vaccines Under the COVID-19 Public Health Response Act 2020 for the Purpose of the Air Border Order

Publication Date
14 Mar 2022

Tags

Statutory specification Health COVID-19 COVID-19 Public Health Response Act COVID-19 Public Health Response (Air Border) Order 2021

Notice Number

2022-go928
Title
View PDF
File Type and Size
PDF (36 KB)

Pursuant to section 5(3)(b) of the COVID-19 Public Health Response Act 2020, I, Dr Ashley Bloomfield, Director-General of Health, hereby declare that the doses of each COVID-19 vaccine or combination of COVID-19 vaccines specified in this notice are required for a person to be “vaccinated” for the purposes of clause 13 of the COVID-19 Public Health Response (Air Border) Order 2021 (“Order”) except for General traveller (A) persons and General traveller (B) persons pursuant to the Order. A combination of vaccine doses will meet the definition where this is the accepted schedule in the place of vaccination.

For the purposes of clause 13 of the Order other than for persons designated General traveller (A) persons and General traveller (B) persons pursuant to the Order vaccinated means being vaccinated against COVID-19 with at least one of the following complete vaccination courses (meaning the combination of COVID-19 vaccine and number of doses in each line):

  • Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2) 2 doses.
  • AstraZeneca (Oxford/AstraZeneca, Vaxzevria, AZD1222, ChAdOx1 nCoV-19) 2 doses.
  • AstraZeneca (Covishield, Serum Institute of India formulation) 2 doses.
  • Moderna (Spikevax, mRNA-1273) 2 doses.
  • Janssen / Johnson & Johnson (Janssen COVID-19 Vaccine, Ad26.COV2.S1, JNJ-78436735) 1 dose.
  • Sinopharm, Beijing (BBIBP-CorV, BiBP vaccine, Covilo) 2 doses.
  • Sinovac (CoronaVac, PiCoVacc) 2 doses.
  • Bharat Biotech (Covaxin, BBV152) 2 doses.
  • Novovax (Nuvaxovid, (NVX-CoV2373) 2 doses.
  • Covovax (Serum Institute of India Novovax) 2 doses.
  • Zifivax (Anhui Zhifei Longcom, ZF2001, ZF-UZ-VAC-2001) 2 doses.
  • Corbevax (Biological E. (BioE) Limited, BECOV2D, BECO2A, BioE COVID-19) 2 doses.
  • CanSino (Convidecia, PakVac, Ad5-nCoV) 2 doses.
  • Abdala (Center for Genetic Engineering and Biotechnology, CIGB-66) 2 doses.
  • KoviVac (Chumakov Centre) 2 doses.
  • EpiVacCorona (Federal Budgetary Research Institution State Research Center of Virology and Biotechnology (FBRI), VECTOR) 2 doses.
  • Aurora-Cov (Federal Budgetary Research Institution State Research Center of Virology and Biotechnology (FBRI) EpiVacCorona-N) 2 doses.
  • Sputnik Light (Gamaleya Research Institute of Epidemiology and Microbiology) 1 dose.
  • Sputnik V (Gamaleya Research Institute of Epidemiology and Microbiology, Gam-COVID-Vac) 2 doses.
  • Tukovac (Health Institutes of Turkey, ERUCOV-VAC) 2 doses.
  • Soberana 02 (Instituto Finlay de Vacunas Cuba, FINLAY-FR-2, Pasteurcovac) 2 doses.
  • Soberana Plus (Instituto Finlay de Vacunas Cuba, FINLAY-FR-1Am (as a 3rd dose after 2 doses of Soberana 02).
  • Qazvac (Khazakstan Research Institute for Biological Safety Problems, RIBSP QazCovid-in) 2 doses.
  • MVC COVID-19 vaccine (Medigen Vaccine Biologics Corporation, MVC-COV1901) 2 doses.
  • KCONVAC (Minhai Biotechnology Co (Beijing), KconecaVac, Minhai COVID-19 Vaccine) 2 doses.
  • Recombinant SARS-CoV-2 Vaccine (CHO Cell) (National Vaccine and Serum Institute (China), NVSI-06-08) Recombinant COVID-19 Vaccine (CHO cell, NVSI-06-08) 3 doses.
  • FAKHRAVAC (Organization of Defensive Innovation and Research (Iran), MIVAC) 2 doses.
  • Rasi Cov Pars (Razi Vaccine and Serum Research Institute (Iran)) 3 doses.
  • COVIran Barekat (Shifa Pharmed Industriall Co(Iran) B1V1-CovIran) 2 doses.
  • Sinopharm (Wuhan) (WIBP-CorV, Inactivated (Vero Cells) 2 doses.
  • Takeda (TAK-919) (Moderna formulation) 2 doses.
  • SpikoGen (Vaxine/CinnaGen Co (Australia), COVAX-19 2 doses.
  • Zydus Cadila (ZyCoV-D) 3 doses.
  • COVIFENZ (Medicago Inc., coVLP) 2 doses.
  • VLA2001 (Valneva SE/Dynavax Technologies, VLA2101) 2 doses.

For the avoidance of doubt, vaccinated for the purposes of clause 13 of the COVID-19 Public Health Response (Air Border) Order 2021 (“Order”) for persons designated General traveller (A) persons and General traveller (B) persons pursuant to the Order means vaccinated in accordance with the Specification of COVID-19 Vaccines under section 5(3) of the COVID-19 Public Health Response Act 2020 Notice.

The notice “Specification of COVID-19 Vaccines Under the COVID-19 Public Health Response Act 2020 for the Purpose of the Air Border Order” made on 25 February 2022 (New Zealand Gazette, 25 February 2022, Notice No. 2022-go678) is revoked.

This notice comes into effect at 12.00pm on 15 March 2022.

Dated at Wellington this 13th day of March 2022.

Dr ASHLEY BLOOMFIELD, Director-General of Health.